Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Novartis, 2012 Is Set To Be A Bumpy Ride

This article was originally published in The Pink Sheet Daily

Executive Summary

With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.

Advertisement

Related Content

Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella
Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets
Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets
Novartis Revises U.S. Regulatory Strategy For Key Respiratory Drug
EU And U.S. Regulators Toughen CV Monitoring Requirements For Novartis's Gilenya
Germany’s Pricing Revolution: Why The World Should Be Watching
EU's CHMP Warns About Boceprevir In HIV, Aliskiren In Diabetes, But Clears Orlistat And Reinstates Trasylol
Revelations And Resolutions, In Brief
With Its Hypertension Franchise in Crisis, Novartis Restructures
Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel